QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
NASDAQ:TMDX

TransMedics Group - TMDX Stock Forecast, Price & News

$69.00
+2.87 (+4.34%)
(As of 01/27/2023 04:03 PM ET)
Add
Compare
Today's Range
$66.02
$69.00
50-Day Range
$53.63
$67.43
52-Week Range
$10.00
$69.00
Volume
224,852 shs
Average Volume
326,881 shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.29

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
21.0% Downside
$53.29 Price Target
Short Interest
Healthy
4.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of TransMedics Group in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$8.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.30) to ($0.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

Medical Sector

999th out of 1,055 stocks

Electromedical Equipment Industry

23rd out of 24 stocks


TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $53.29
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
TMDX TransMedics Group, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
TMDX.OQ - | Stock Price & Latest News | Reuters
TransMedics Group Reaches Analyst Target Price
My Top Pick For 2023: TransMedics Group
TransMedics Remains A Buy Heading Into Q3 Earnings
5 Analysts Have This to Say About TransMedics Group
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.29
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
-22.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-44,220,000.00
Pretax Margin
-58.69%

Debt

Sales & Book Value

Annual Sales
$30.26 million
Book Value
$2.44 per share

Miscellaneous

Free Float
29,147,000
Market Cap
$2.20 billion
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Waleed H. HassaneinWaleed H. Hassanein
    President, Chief Executive Officer & Director
  • John F. CareyJohn F. Carey
    Vice President-Operations
  • Stephen GordonStephen Gordon
    Chief Financial Officer, Secretary & Treasurer
  • Mark Anderson
    Senior Director-Technology Development
  • John Sullivan
    Vice President-Quality & Engineering













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

7 analysts have issued 1-year price objectives for TransMedics Group's shares. Their TMDX share price forecasts range from $39.00 to $70.00. On average, they expect the company's share price to reach $53.29 in the next twelve months. This suggests that the stock has a possible downside of 19.4%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2023?

TransMedics Group's stock was trading at $61.72 at the beginning of the year. Since then, TMDX shares have increased by 7.1% and is now trading at $66.13.
View the best growth stocks for 2023 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Thursday, November, 3rd. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.15. The company had revenue of $25.68 million for the quarter, compared to the consensus estimate of $18.96 million. TransMedics Group had a negative trailing twelve-month return on equity of 46.03% and a negative net margin of 58.78%.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $75.66 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (1.87%), Baillie Gifford & Co. (0.79%), Peregrine Capital Management LLC (0.42%), Calamos Advisors LLC (0.19%), Park Avenue Securities LLC (0.04%) and Dupont Capital Management Corp (0.02%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $66.13.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.11 billion and generates $30.26 million in revenue each year. The company earns $-44,220,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 1/27/2023 by MarketBeat.com Staff